# PharmaPolySCOPE Viva School -- Phase Status

**Curriculum root:**
`C:\Users\Admin\Documents\GitHub\Knowledge-OS\Knowledge-OS\Areas\Research\Thesis\meow nadh karti kay\PharmaPolySCOPE_Viva_School\`

**Repository inspected (read-only):**
`C:\Users\Admin\.gemini\antigravity\scratch\asd_framework`

---

## Phase 1 Status: FORENSIC CORRECTION COMPLETE

### Version History

| Version | Date | Status |
|---------|------|--------|
| v1.0 | 2026-09-14 (initial creation) | SUPERSEDED -- contained material errors |
| v1.1 | 2026-09-14 (forensic correction) | **CURRENT -- authoritative** |

### Phase 1 Deliverables

| File | Status | Size |
|------|--------|------|
| `00_MASTER_KNOWLEDGE_MAP\PHARMAPOLYSCOPE_MASTER_KNOWLEDGE_MAP.md` | v1.1 CORRECTED | ~46 KB |
| `00_MASTER_KNOWLEDGE_MAP\PHASE1_CORRECTION_LOG.md` | CREATED | ~7 KB |
| `PHASE_STATUS.md` | UPDATED (this file) | -- |

---

### Material Errors Corrected in v1.1

| # | Error | Severity |
|---|-------|----------|
| 1 | Wrong AHP pairwise matrix (used [[1,2,5,3],...] instead of [[1,2,3,2],...]) | **CRITICAL** |
| 2 | Monte Carlo replicates stated as 2,000 (correct: 10,000 generated, 8,600 valid) | **CRITICAL** |
| 3 | Polymer cohort included HPMCAS-MF (not in active library) and wrong IDs (POL-008/009) | **CRITICAL** |
| 4 | Only Indomethacin Ranks 1-2 shown (all 5 now included with correct C_L values) | SIGNIFICANT |
| 5 | p_top1 framed as "probability of success" (corrected to "computational top-1 frequency") | SIGNIFICANT |
| 6 | DRG-0002 framing incomplete (input-governance vs scientific-validity distinction missing) | SIGNIFICANT |
| 7 | Legacy v1.5 tests framed as "proving v1.5 was wrong" (corrected) | SIGNIFICANT |
| 8 | "PCA identifies important criteria" overstatement (corrected) | Minor terminology |

---

### Source Files Forensically Inspected

| File | What Was Verified |
|------|------------------|
| `backend/services/engine_adapter.py` lines 95-104 | AUTHORITATIVE_V2_AHP_MATRIX [[1,2,3,2],...] |
| `tests/v2/conftest.py` lines 203-217 | AHP matrix fixture confirmation |
| `src/asd_mcda/v2/uncertainty.py` lines 141-200 | MC default num_replicates=10000 |
| `config/polymers/polymer_library_v3_five_polymers.csv` | Five polymer IDs and names |
| `results/validation/v2_scientific_validation/scientific_validation_results.json` | Full validation data (all fields) |
| `config/ahp/default_matrix.json` | Legacy 2x2 PC-space config (historical, not used by v2 production) |
| `config/ahp/expert_001/002/003.json` | Expert 2x2 matrices (historical PC-space, not v2 production) |

### Validation Artifact Data Extracted

| JSON key | Value verified |
|---------|---------------|
| AHP weights | [0.40767478, 0.32443341, 0.09216134, 0.17573047] |
| lambda_max | 4.131937073898666 |
| CI | 0.04397902463288853 |
| CR | 0.04941463441897588 |
| K (Indomethacin) | 3 |
| cumulative_variance | 0.99963393063776 |
| boundary_eigengap | 0.7383104290964133 |
| MC num_replicates | 10000 |
| MC num_valid_replicates | 8600 |
| MC num_blocked_replicates | 1400 |
| AHP_CR_BLOCKED | 1396 |
| EIGENGAP_BLOCKED | 4 |
| Soluplus C_L | 0.6864350839750771 |
| Soluplus p_top1 | 0.5551162790697675 (55.51%) |
| HPMC E5 C_L | 0.6731464918436223 |
| HPMC E5 p_top1 | 0.42 (42.00%) |
| All 5 polymer ranks and C_L values | Verified |

---

### Consistency Scan (Post-Correction v1.1)

- [x] AHP matrix = [[1,2,3,2],[0.5,1,5,2],[1/3,0.2,1,0.5],[0.5,0.5,2,1]] -- consistent
- [x] AHP weights [0.40767478, 0.32443341, 0.09216134, 0.17573047] -- consistent throughout
- [x] CR = 0.049415 < 0.08 [ACCEPTED] -- consistent throughout
- [x] Polymer cohort = PVP K30, PVP-VA64, Soluplus, HPMC E5, Eudragit E PO -- no HPMCAS-MF
- [x] MC: N_generated=10,000 / N_valid=8,600 / N_blocked=1,400 -- consistent throughout
- [x] Indomethacin: all 5 rankings from validation JSON -- consistent
- [x] v1.5 / v2 terminology -- consistently separated, never collapsed
- [x] SP-PRP-TOPSIS formula: D_i notation, M_K correctly defined -- consistent
- [x] No "best polymer" overclaim -- none found
- [x] No "probability of success" language -- none found
- [x] No HPMCAS-MF as active cohort member -- none found
- [x] p_top1 explicitly qualified "over 8,600 valid replicates" -- consistent
- [x] DRG-0002: input-governance vs scientific-validity distinction explicit
- [x] Legacy tests: "preserve historical v1.5 contract" framing -- consistent

---

### Remaining Uncertainties (LOW)

| # | Uncertainty | Impact |
|---|-------------|--------|
| 1 | `src/asd_mcda/v2/metrics.py` lines 100-306 not directly read. D_i+ / D_i- formula confirmed via engine.py and validation JSON but not line-verified in metrics.py. | LOW |
| 2 | Ibuprofen and Itraconazole full 5-polymer rankings not extracted from JSON (not required for Phase 1). | LOW |
| 3 | `default_matrix.json` contains a legacy 4x4 `raw_pairwise_matrix` that differs from the authoritative matrix. Confirmed it is NOT used by v2 production code (v2 uses engine_adapter.py hardcoded AUTHORITATIVE_V2_AHP_MATRIX). | DOCUMENTED -- no action |

---

## Phase 1 Recommendation

**APPROVED FOR PHASE 2**

Rationale:
- All three CRITICAL errors (AHP matrix, MC replicates, polymer cohort) corrected and
  source-verified against production code and validated artifacts.
- All SIGNIFICANT framing corrections applied (DRG-0002, legacy tests, p_top1 interpretation).
- PHASE1_CORRECTION_LOG.md documents every change with conflict log and source attribution.
- All 14 curriculum folders and 99_INDEXES remain stubbed for Phase 2 population.
- Remaining uncertainties are LOW and do not affect viva-readiness of Phase 1 material.

**Phase 2 may proceed upon user approval.**

---

## Phase 2 Plan (Awaiting User Approval)

**Priority 1 (Examination-Critical):**
- `04_MATHEMATICS\STEP_BY_STEP_MATH.md` -- Full worked derivations with Indomethacin numbers
- `09_VIVA_ATTACK_FILES\ATTACK_AND_RESPONSE.md` -- 20+ Q&A at PhD level
- `12_NUMBERS_YOU_MUST_KNOW\FLASHCARDS.md` -- Spaced-repetition card set
- `13_DO_NOT_SAY_THIS_IN_VIVA\FORBIDDEN_PHRASES_EXTENDED.md` -- Full explanations

**Priority 2 (Deep Understanding):**
- `01_PHARMACEUTICAL_FOUNDATIONS\ASD_SCIENCE.md`
- `02_CHEMICAL_INFORMATICS\RDKIT_AND_DESCRIPTORS.md`
- `03_COMPATIBILITY_CRITERIA\FOUR_CRITERIA_DEEP_DIVE.md`
- `07_SOFTWARE_ARCHITECTURE\VERSION_SEMANTICS_V15_V2.md`
- `08_VALIDATION_REPRODUCIBILITY\DRG0002_INCIDENT_DETAILED.md`

**Priority 3 (Defence Exercises):**
- `10_REVERSE_ENGINEERING\INDOMETHACIN_NUMERICAL_TRACE.md`
- `11_COUNTERFACTUAL_LAB\WHAT_IF_EXPERIMENTS.md`
- `14_BOARD_EXPLANATIONS\WHITEBOARD_SCRIPTS.md`

---

## Phase 3 Status: MODULE 06 — FORENSIC RECONSTRUCTION COMPLETE

**Open Defects:** 0  
**Historical Defects Repaired:** 34 (7 P0, 12 P1, 12 P2, 3 P3)  
**Status:** READY FOR PHASE 3 CLOSURE  
**Standard:** Implementation-aligned and viva-defensible within the documented computational scope.

### Reconstruction Summary (2026-09-15)
- **Scope:** Modules 05 & 06 (15 documents total, 354 KB, 3,558 lines).
- **Module 06 Dedicated Forensic Audit:** All 29 directives resolved across all 8 documents.
- **Defect Tracking:** Historical defect count = 34; Open defect count = 0.
- **Forbidden Phrases:** 0 hits across all files (eliminated all claims of "proves stability", "topologically invariant", "physically realistic", "zero drift", etc.).
- **Numerical Alignment:** Aligned with source code and `scientific_validation_results.json` (HPMC E5 $p_{top1}=42.00\%$, Soluplus $55.51\%$, $N_{valid}=8,600$, eigengap threshold $\delta_K < 0.03$, $C_L$ argmax).
- **Epistemological Distinction:** Explicitly distinguishes numerical consistency from empirical scientific validity.
- **Micro-Forensic Alignment:** Corrected reciprocity bound ($|a_{ji} a_{ij} - 1| < 10^{-12}$), high-noise non-uniformity bounds, and Monte Carlo SE precision framing ($SE_{max} \approx 0.54\%$).
- **Q&A Reconstruction:** Replaced duplicate Q&A in Docs 05, 06, and 07 with 40 genuinely distinct, structured 5-part defense items each (320 distinct viva items in Module 06).
- **Audit Reports Filed:** `06_UNCERTAINTY_SENSITIVITY/MODULE_06_FINAL_MICRO_FORENSIC_CLOSURE.md`, `06_UNCERTAINTY_SENSITIVITY/PHASE_3_RECONSTRUCTION_AUDIT.md`, and `PHASE_3_REVIEW.md`.

---

*PHASE_STATUS.md -- Last updated 2026-09-15 (Module 06 forensic reconstruction complete; 0 open defects)*


---

## Phase 4 Status: MODULE 07 — FINAL MICRO-FORENSIC CLOSURE APPROVED

**Date:** 2026-09-16  
**Module:** 07 — Software Architecture  
**Corpus Size:** 8 Documents | 477,757 Bytes (~478 KB) | 4,739 Lines  
**Final Status:** **A — APPROVED FOR MODULE 07 FREEZE**  
**Open Defects:** 0 (P0=0, P1=0, P2=0, P3=0)  
**Historical Defects Repaired:** 10 (0 P0, 4 P1, 4 P2, 2 P3)  
**Standard:** Implementation-aligned, source-traceable, and computationally verified within the documented PharmaPolySCOPE scope; does not constitute experimental formulation validation.

### Final Verification Highlights:
- **`01_SOFTWARE_ARCHITECTURE_FROM_ZERO.md`**: Software architecture from first principles; separation of concerns; statelessness; four-tier versioning hierarchy with full commit hash `31eee4d9bb1cc57b9185f9f958e225d51634c871`.
- **`02_PROJECT_STRUCTURE_AND_MODULE_MAP.md`**: Authoritative source tree map; responsibility matrix for all 15 modules in `src/asd_mcda/v2/`; FastAPI backend routes and adapter layer; ASCII dependency graph.
- **`03_DATA_FLOW_INPUT_TO_OUTPUT.md`**: 15-stage conceptual pipeline (Section 2.1) strictly decoupled from verified major runtime call relationships for the documented Research screening path (Section 2.2).
- **`04_V2_VARIABLE_K_ENGINE.md`**: Variable-$K$ SP-PRP-TOPSIS paradigm; dynamic $K$ selection ($	au_{var} = 0.95$); eigengap-based subspace stability governance heuristic ($\delta_K \ge 0.10, 0.03$).
- **`05_WEB_API_AND_EXECUTION_MODES.md`**: Decoupled web architecture; Engine Adapter pattern; Research vs. Exploratory mode gating; mathematical value fidelity (Section 3.4: adapter orchestration != mathematical recomputation != presentation).
- **`06_VALIDATION_ERROR_HANDLING_AND_GOVERNANCE.md`**: Four-tier error defense taxonomy; AST-verified 19-class exception hierarchy (`PharmaPolyScopeV2Error`); replicate conservation law; six canonical block reasons; Morris whole-trajectory discard policy.
- **`07_PROVENANCE_REPRODUCIBILITY_AND_AUDIT_TRAIL.md`**: Computational reproducibility limits; floating-point non-associativity; two-pass non-circular SHA-256 manifest hashing; rejection of universal bitwise identity.
- **`08_SOFTWARE_ARCHITECTURE_VIVA_DEFENSE.md`**: Master viva defense file; exactly 40 unique questions across 4 tiers; programmatic AST verification confirms 40/40 questions have exact 5-part model structure.
- **Audit & Review Files Filed:** `07_SOFTWARE_ARCHITECTURE/PHASE_4_FINAL_MICRO_FORENSIC_CLOSURE.md`, `PHASE_4_FINAL_MICRO_FORENSIC_CLOSURE.md`, `PHASE_4_SECOND_LEVEL_FORENSIC_AUDIT.md`, `PHASE_4_FORENSIC_AUDIT.md`, and `PHASE_4_REVIEW.md`.

---

*PHASE_STATUS.md -- Last updated 2026-09-16 (Phase 4 Module 07 final micro-forensic closure complete; APPROVED FOR FREEZE; 0 open defects)*



---

## Phase 5 Status: MODULE 08 — FINAL MICRO-FORENSIC CLOSURE APPROVED

**Date:** 2026-09-16  
**Module:** 08 — Validation & Reproducibility  
**Corpus Size:** 8 Primary Teaching Documents + 3 Review/Audit Reports | 325,305 Bytes (~325 KB) | 3,050 Lines  
**Final Status:** **A — APPROVED FOR MODULE 08 FREEZE**  
**Open Defects:** 0 (P0=0, P1=0, P2=0, P3=0)  
**Historical Defects Repaired:** 6 (RDKit cross-environment phrasing, DRG-0002 density claim, audit denominator scoping, negative disclaimer scan, class B limitation, numerical reconciliation)  
**Standard:** Implementation-aligned, source-traceable, and computationally verified within the documented PharmaPolySCOPE scope; does not constitute experimental formulation validation.

### Generated Curriculum Inventory:
- **`01_VALIDATION_FROM_ZERO.md`**: Core validation taxonomy from first principles; ASME V&V 10/40 standards; 6-tier epistemology; 10 layered Q&A.
- **`02_SCIENTIFIC_VALIDATION_VS_SOFTWARE_VALIDATION.md`**: Model-code duality; why 100% test pass does not equal biological validity; multi-cohort comparative study; 10 layered Q&A.
- **`03_UNIT_INTEGRATION_AND_SYSTEM_TESTING.md`**: Solving the Test Oracle Problem (Weyuker, 1982); inventory of 116 v2 production tests across 15 files, 29 chemistry tests, 15 RDKit unit tests, 4 isolation tests; 10 layered Q&A.
- **`04_PHARMAPOLYSCOPE_V2_VALIDATION_STUDY.md`**: Multi-cohort study (`VAL-RPT-2026-V2-001-REV1`); Indomethacin ($K=3, 99.9634\%$), Ibuprofen ($K=2$), Itraconazole ($K=2$), DRG-0002 quarantined; v1.5 fixed $K=2$ vs v2 dynamic $K$ reconciliation; 10 layered Q&A.
- **`05_REPRODUCIBILITY_AND_PROVENANCE.md`**: Repeatability vs Replicability vs Reproducibility; limits of `seed=42`; IEEE 754 non-associativity; two-pass non-circular SHA-256 manifest hashing; Class B environment limitation; 10 layered Q&A.
- **`06_INPUT_DATA_AND_CHEMISTRY_INTEGRITY.md`**: GIGO problem; 6 functions in `chemistry.py`; `ProductionFallbackProhibitedError`; DRG-0002 forensic case study; copolymer pipe delimiter parsing; 10 layered Q&A.
- **`07_VALIDATION_FAILURES_AND_LIMITATIONS.md`**: Epistemology of controlled blocking; 6 canonical block reasons; Replicate Conservation Law ($10,000 = 8,600 + 1,400$); Morris whole-trajectory discard; 6 scientific limitations; 10 layered Q&A.
- **`08_VALIDATION_VIVA_DEFENSE.md`**: Master Viva Defense File; exactly 40 unique questions (Q1–Q40) across 4 tiers; programmatic verification confirms 40/40 questions possess the exact 5-part model structure ($40 \times 5 = \text{PASS}$).
- **Audit & Review Files Filed**:
  * `08_VALIDATION_REPRODUCIBILITY/PHASE_5_REVIEW.md`
  * `08_VALIDATION_REPRODUCIBILITY/PHASE_5_FORENSIC_AUDIT.md`
  * `08_VALIDATION_REPRODUCIBILITY/PHASE_5_FINAL_MICRO_FORENSIC_CLOSURE.md`

---

*PHASE_STATUS.md -- Last updated 2026-09-16 (Phase 5 Module 08 final micro-forensic closure complete; APPROVED FOR FREEZE; 0 open defects)*
